Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985. https://doi.org/10.1016/j.eclinm.2021.100985.
 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia‐Pacific Journal of Clinical Oncology. 2017;13(4):289-95. https://doi.org/10.1111/ajco.12661.
 Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunology, Immunotherapy. 2012;61:239-47. https://doi.org/10.1007/s00262-011-1148-6.
 Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clinical Chemistry and Laboratory Medicine (CCLM). 2013;51(1):99-112. https://doi.org/10.1515/cclm-2012-0496.
 Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours. The Journal of pathology. 2014;232(2):199-209. https://doi.org/10.1002/path.4287.
 Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer. 2012 Apr;12(4):298-306. https://doi.org/10.1038/nrc3245.
 Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. Breast disease. 2020;39(2):61-9. https://doi.org/10.3233/BD-200442.
 Helal TE, Ibrahim EA, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian Journal of Pathology and Microbiology. 2013;56(2):89.
 Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, et al. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast cancer research and treatment. 2014;143:1-9. https://doi.org/10.1007/s10549-013-2781-x.
 Kolarov-Bjelobrk I, Ivkovic-Kapicl T, Jovanovic D, Trifunovic J, Radic J, Vidovic V. Clinical relevance of determination of tumour infiltrating lymphocytes in breast carcinoma. West Indian Med J. 2017. https//doi.org/10.7727/wimj.2017.044.
 Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of oncology. 2015;26(2):259-71. https://doi.org/10.1093/annonc/mdu450.
 Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. The Indian journal of medical research. 2014;140(3):361-9.
 Bhatia A, Kumar Y, Tumour Infiltrating Lymphocytes: Changing Trends. Clinics in Oncology. 2018;3:1409.
 Al-Attar A, Shehata M, Durrant L, Moseley P, Deen S, Chan S. T cell density and location can influence the prognosis of ovarian cancer. Pathology & Oncology Research. 2010;16:361-70. https://doi.org/10.1007/s12253-009-9230-5.
 Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clinical Cancer Research. 2007;13(2):388-97. https://doi.org/10.1158/1078-0432.CCR-06-1734.
 Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of oncology. 2014;25(8):1544-50. https://doi.org/10.1093/annonc/mdu112.
 Macchetti AH, Marana HR, Silva JS, Andrade JM, Ribeiro-Silva A, Bighetti S. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics. 2006;61(3):203-8. https://doi.org/10.1590/S1807-59322006000300004